肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

2018年WCLC：Atezolizumab治疗IV期非鳞状非小细胞肺癌的有效性和安全性

2018-09-28 MedSci MedSci原创

atezolizumab非鳞状非小细胞肺癌WCLC
关注

在第19届世界肺癌大会（WCLC）上，III期临床试验（IMpower132试验）的中期结果正式公布，Atezolizumab在治疗IV期非鳞状非小细胞肺癌（NSCLC）方面表现出积极的有效性和安全性。

在第19届世界肺癌大会（WCLC）上，III期临床试验（IMpower132试验）的中期结果正式公布，Atezolizumab在治疗IV期非鳞状非小细胞肺癌（NSCLC）方面表现出积极的有效性和安全性。该试验评估了Atezolizumab联合培美曲塞、卡铂或顺铂对无进展生存期（PFS）和总生存期（OS）的影响。

德克萨斯大学安德森癌症中心医学博士Vassiliki A. Papadimitrakopoulou说：“IMpower132在意向治疗人群中实现了它的主要终点。Atezolizumab联合培美曲塞、卡铂或顺铂的疗法具有可控的安全性，符合各种已知的安全标准”。Papadimitrakopoulou博士及其同事将患有IV期非鳞状NSCLC的患者（n = 578）随机分组接受4或6个周期的卡铂或顺铂以及培美曲塞（500 mg/ m2）治疗（PP组，n = 286）或这些药物与Atezolizumab联合使用（APP组，n = 292）。该治疗阶段完成之后是维持期，其中PP组使用的是培美曲塞维持治疗，APP组使用的是Atezolizumab+培美曲塞维持治疗。


原始出处：

http://www.firstwordpharma.com/node/1593505#axzz5SJBcSQbc

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059750, encodeId=97f82059e50df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Oct 09 17:51:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912042, encodeId=bcc319120421f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Oct 23 11:51:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312140, encodeId=07ff13121409b, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99774, encryptionId=6c1099e74ad, topicName=非鳞状非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun Sep 30 11:51:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412359, encodeId=b80b14123597b, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Sun Sep 30 11:51:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2018-10-09 lingaifan

    #非小细胞#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2059750, encodeId=97f82059e50df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Oct 09 17:51:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912042, encodeId=bcc319120421f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Oct 23 11:51:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312140, encodeId=07ff13121409b, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99774, encryptionId=6c1099e74ad, topicName=非鳞状非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun Sep 30 11:51:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412359, encodeId=b80b14123597b, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Sun Sep 30 11:51:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2018-10-23 snf701207

    #mAb#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2059750, encodeId=97f82059e50df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Oct 09 17:51:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912042, encodeId=bcc319120421f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Oct 23 11:51:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312140, encodeId=07ff13121409b, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99774, encryptionId=6c1099e74ad, topicName=非鳞状非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun Sep 30 11:51:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412359, encodeId=b80b14123597b, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Sun Sep 30 11:51:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2018-09-30 weihongyv

    #非鳞状非小细胞肺癌#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2059750, encodeId=97f82059e50df, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Oct 09 17:51:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912042, encodeId=bcc319120421f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Oct 23 11:51:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312140, encodeId=07ff13121409b, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99774, encryptionId=6c1099e74ad, topicName=非鳞状非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun Sep 30 11:51:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412359, encodeId=b80b14123597b, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18637, encryptionId=de711863ed3, topicName=WCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91252863770, createdName=木头人514, createdTime=Sun Sep 30 11:51:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2018-09-30 木头人514

    #WCLC#

    0

相关资讯

NEJM：Atezolizumab一线治疗转移性非鳞状非小细胞肺癌

研究发现，Atezolizumab、贝伐单抗联合化疗可显著延长转移性非鳞状非小细胞肺癌患者无进展生存期以及总生存期，该效果不受PD-L1表达、EGFR以及ALK等基因突变的影响

Lancet：Atezolizumab不能延长PD-L1过表达的铂难治性转移性尿路上皮癌患者生存期

研究认为，对于PD-L1过表达的铂难治性转移性尿路上皮癌患者，Atezolizumab治疗相比于化疗不能显著延长患者总生存期，但治疗副作用更低

Lancet：非小细胞肺癌患者是用多西他赛还是Atezolizumab？

该研究报告了PD-L1靶向治疗的效果，用Atezolizumab治疗比多西他赛能更好地改善以往治疗过的非小细胞肺癌患者临床相关的总体生存期，无论PD-L1的表达或肿瘤组织学特征，Atezolizumab治疗均具有良好的安全性。

FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌

FDA于今日批准了首个PD-L1抑制剂罗氏Tecentriq (atezolizumab)用于治疗局部晚期或转移性尿路上皮癌患者的二线治疗，当患者铂类药物化疗期间或之后病情恶化、手术前后铂类药物化疗1年内病情恶化，可以考虑选择该药物。atezolizumab的安全性和有效性研究中纳入了310名使用铂类药物化疗后病情恶化的局部晚期或转移性尿路上皮癌患者，每三周静脉给药一次atezolizumab 1

Lancet：Atezolizumab可显著提高非小细胞肺癌（NSCLC）患者的生存率

以前经过治疗的，晚期或转移性非小细胞肺癌（NSCLC）患者预后较差。抗程序性死亡配体1（PD-L1的）抗体atezolizumab针对癌症，包括NSCLC具有临床活性，特别是对于肿瘤细胞和肿瘤浸润免疫细胞表达PD-L1的癌症，或两者均表达的癌症。研究人员评估了多西紫杉醇和atezolizumab对于之前经过治疗的NSCLC的安全性和疗效，由PD-L1在肿瘤细胞和肿瘤浸润免疫细胞的表达水平进行分析，

新药速递：Atezolizumab在欧洲被批准用于治疗肺癌和膀胱癌

欧洲委员会已经授权Atezolizumab(Tecentriq)用于治疗局部晚期或转移性非小细胞肺癌(NSCLC)和局部晚期或转移性尿路上皮癌(mUC)。